Comparative efficacy of interventional therapy with or without targeted immunotherapy in Child-Pugh B hepatocellular carcinoma patients: a single-center, retrospective study
BackgroundCurrent large clinical trials mainly focus on Child-Pugh A (CP-A) stage hepatocellular carcinoma (HCC) patients, with limited data on CP-B patients especially those classified as B8-9, whose treatment needs remain inadequately addressed. This study aims to evaluate the safety efficacy of i...
Saved in:
| Main Authors: | Xu-Wei Guo, Man Zhao, Xiao-Ling Duan, Guang-Jie Han, Jin-Feng Wang, Jian-Fei Shi, Xin Han, Fei Yin, Guang Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1541805/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study
by: Xiaoyan Ding, et al.
Published: (2025-05-01) -
Triple Therapy with Interventional Treatment, Donafenib, and Anti-PD-1 Antibodies in Unresectable Hepatocellular Carcinoma: A Retrospective Real-World Study in China
by: Ye Q, et al.
Published: (2025-08-01) -
Role of Immunotherapy in the Treatment of Hepatocellular Carcinoma
by: Irina Y. Dobrosotskaya, et al.
Published: (2025-04-01) -
Adding dendritic cell-immunotherapy for post-transplant hepatocellular carcinoma recurrence
by: Wei-Chen Lee, et al.
Published: (2025-08-01) -
First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors
by: Yanjun Shen, et al.
Published: (2025-05-01)